Patents by Inventor Bradley V. Clineschmidt

Bradley V. Clineschmidt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-emetic esters of cyproheptadine-3-carboxylic acid and structurally related compounds
    Patent number: 4522821
    Abstract: Certain esters of cyproheptadine-3-carboxylic acid and its bioisosteres are peripherally selective dopamine antagonists useful in the treatment of emesis caused by stimulation of dopamine receptors of the chemoreceptor trigger zone, as well as emesis and nausea resulting from other causes including post operative emesis, chronic pediatric vomiting, radiotherapy and chemotherapy induced emesis, and nausea associated with migraine attacks and dysmenorrhea or arising idiopathically.They are also useful in the treatment of gastrointestinal disorders, such as gastro-oesophageal reflux caused by stimulation of dopamine receptors in the stomach or other causes and dyspepsia arising from delayed gastric emptying, post prandial dyspepsia or dyspepsia of unknown etiology.
    Type: Grant
    Filed: August 8, 1983
    Date of Patent: June 11, 1985
    Assignee: Merck & Co., Inc.
    Inventors: David C. Remy, Bradley V. Clineschmidt
  • Peripherally selective dopamine antagonists in the treatment of ocular hypertension
    Patent number: 4501749
    Abstract: Peripherally selective dopamine antagonists are useful in the treatment of ocular hypertension when administered topically to the eye.
    Type: Grant
    Filed: October 31, 1983
    Date of Patent: February 26, 1985
    Assignee: Merck & Co., Inc.
    Inventor: Bradley V. Clineschmidt
  • Anti-emetic esters of cyproheptadine-3-carboxylic acid and structurally related compounds
    Patent number: 4412999
    Abstract: Certain esters of cyproheptadine-3-carboxylic acid and its bioisosteres are peripherally selective dopamine antagonists useful in the treatment of emesis caused by stimulation of dopamine receptors of the chemoreceptor trigger zone, as well as emesis and nausea resulting from other causes including post operative emesis, chronic pediatric vomiting, radiotherapy and chemotherapy induced emesis, and nausea associated with migrane attacks and dysmenorrhea or arising idiopathically.They are also useful in the treatment of gastrointestinal disorders, such as gastro-oesophageal reflux caused by stimulation of dopamine receptors in the stomach or other causes and dyspepsia arising from delayed gastric emptying, post prandial dyspepsia or dyspepsia of unknown etiology.
    Type: Grant
    Filed: April 14, 1982
    Date of Patent: November 1, 1983
    Assignee: Merck & Co., Inc.
    Inventors: David C. Remy, Bradley V. Clineschmidt